MNO and Public Health Ontario sign Agreement to advance Métis health priorities - Métis Nation of Ontario

The Métis Nation of Ontario is seeking input from Métis-owned businesses to better understand how U. S. tariffs, changing trade conditions, and broader economic uncertainty are affecting businesses across Ontario. The MNO’s Economic Development Branch has launched a short survey for MNO citizens who own or operate businesses in Ontario. The survey was developed following a request from Kathleen Anderson, PCMNO Economic Development Portfolio Holder, to better understand what Métis-owned businesses are experiencing and what supports may be needed. The survey asks business owners about the impacts they are currently experiencing, what they anticipate in the months ahead, and the types of support that would be most helpful. Businesses are invited to share whether they have experienced challenges such as increased costs, supply-chain disruptions, reduced sales or customer demand, difficulties accessing U. S. markets, workforce impacts, cash-flow pressures, or uncertainty when making business decisions.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.